GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)

References

• Li N, Wang LJ, Jiang B, et al. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Eur J Med Chem. 2018;151:145–157.
   PubMed Web of Science ®Google Scholar
• Fang Y, Yang Z, Gundeti S, et al. Novel 5-nitropyrimidine derivatives bearing endo-azabicyclic alcohols/amines as potent GPR119 agonists. Bioorg Med Chem. 2017;25:254–260.
   PubMed Web of Science ®Google Scholar
• IDF diabetes atlas 9th edition, 2019. [cited 2020 Dec 20]. Available from: https://diabetesatlas.org/en/[Last
   Google Scholar
• Boehm M, Crawford M, Moscovitz JE, et al. Diabetes area patent participation analysis – part II: years 2011-2016. Expert Opin Ther Pat. 2018;28:111–122.
   PubMed Web of Science ®Google Scholar
• Matsuda D, Kawamura M, Kobashi Y, et al. Design, synthesis and biological evaluation of novel 7-azaspiro[3.5]nonane derivatives as GPR119 agonists. Bioorg Med Chem. 2018;26:1832–1847.
   PubMed Web of Science ®Google Scholar
• Yu CG, Fu Y, Fang Y, et al. Fighting type-2 diabetes: present and future perspectives. Curr Med Chem. 2019;26:1891–1907.
   PubMed Web of Science ®Google Scholar
• Yang Z, Fang Y, Park H. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist. Bioorg Med Chem Lett. 2017;27:2515–2519.
   PubMed Web of Science ®Google Scholar
• Kang SU. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discov Today. 2013;18:1309–1315.
   PubMed Web of Science ®Google Scholar
• Ohishi T, Yoshida S. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Inv Drug. 2012;21:321–328.
   PubMed Web of Science ®Google Scholar
• Overton HA, Fyfe MCT, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153:S76–81.
   PubMed Web of Science ®Google Scholar
• Fredriksson R, Höglund PJ, Gloriam DE, et al. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett. 2003;554:381–388.
   PubMed Web of Science ®Google Scholar
• Shah U, Kowalski TJ. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Vitam Horm. 2010;84:415–448.
   PubMed Web of Science ®Google Scholar
• Odori S, Hosoda K, Tomita T, et al. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism. 2013;62:70–78.
   PubMed Web of Science ®Google Scholar
• Little TJ, Isaacs NJ, Young RL, et al. Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index. Am J Physiol Gastrointest Liver Physiol. 2014;307:G958–967.
   PubMed Web of Science ®Google Scholar
• Dhayal S, Morgan NG. The significance of GPR119 agonists as a future treatment for type 2 diabetes. Drug News Perspect. 2010;23:418–424.
   PubMedGoogle Scholar
• Chepurny OG, Holz GG, Roe MW, et al. GPR119 agonist AS1269574 activates TRPA1 cation channels to stimulate GLP-1 secretion. Mol Endocrinol. 2016;30:614–629.
   PubMedGoogle Scholar
• Jones RM, Leonard JN. The emergence of GPR119 agonists as anti-diabetic agengs. Annu Rep Med Chem. 2009;44:149–170.
   Web of Science ®Google Scholar
• Li NX, Brown S, Kowalski T, et al. GPR119 agonism increases glucagon secretion during insulin-induced hypoglycaemia. Diabetes. 2018;67:1401–1413.
   PubMed Web of Science ®Google Scholar
• Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006;3:167–175.
   PubMed Web of Science ®Google Scholar
• Chu ZL, Carroll C, Chen R, et al. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol. 2010;24:161–170.
   PubMed Web of Science ®Google Scholar
• Syed SK, Bui HH, Beavers LS, et al. Regulation of GPR119 receptor activity with endocannabinoid-like lipids. Am J Physiol Endocrinol Metab. 2012;303:E1469–E1478.
   PubMed Web of Science ®Google Scholar
• Moran BM, Abdel-Wahab YHA, Flatt PR, et al. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice. Biol Chem. 2014;395:453–464.
   PubMed Web of Science ®Google Scholar
• Kleberg K, Hassing HA, Hansen HS. Classical endocannabinoid-like compounds and their regulation by nutrients. BioFactors. 2014;40:363–372.
   PubMed Web of Science ®Google Scholar
• Ritter K, Buning C, Halland N, et al. G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J Med Chem. 2016;59:3579–3592.
   PubMed Web of Science ®Google Scholar
• Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem. 2008;51(17):5172–5175.
   PubMed Web of Science ®Google Scholar
• Fevig JM, Wacker DA [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists. WO2008137435. 2008.
   Google Scholar
• Neelamkavi SF, Boyle CD, Harris JM, et al. Bicyclic heterocycle derivatives and their use as GPCR modulators. WO2010009207. 2010.
   Google Scholar
• Neustadt BR, Stamford A, Hao J, et al. Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes. WO2010075269. 2010.
   Google Scholar
• Neelamakavil SF, Boyle CD, Chackalamannil S, et al. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators. WO2010009195. 2010.
   Google Scholar
• Heckel A, Himmelsbach F, Langkopf E, et al. Substituted piperidines as GPR119 modulators for the treatment of metabolic disorders. WO2012168315A1. 2012.
   Google Scholar
• Jones RM, Buzard DJ, Han S, et al. Modulators of the GPR119 receptor and the treatment of disorders related thereto. WO2012170702. 2012.
   Google Scholar
• Darout E, Guimaraes C, Mascitti V, et al. GPR119 modulators. WO2013011402. 2013.
   Google Scholar
• Fell JB, Fischer JP, Hinklin RJ Piperidinyl-substituted cyclic ureas as gpr119 modulators. US20140309226. 2014.
   Google Scholar
• Broekema M, Wu G, Wacker DA Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators. US9174965. 2015.
   Google Scholar
• Shintani Y, Niwa M, Monma S, et al. Preparation of substituted azole compounds as GPR119 agonists for the treatment of diabetes and obesity. JP2017119628. 2017.
   Google Scholar
• Mansour TS, Chafeev M, Yudin M, et al. Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119. WO2017210794. 2017.
   Google Scholar
• Patil RI, Gunjal AP, Verma J, et al. Preparation of heterocyclic compounds as GPR119 agonist for treatment of metabolic disorders. WO2017175066. 2017.
   Google Scholar
• Patil RI, Verma J, Shah D, et al. Preparation of thiazolopyridine derivatives as GPR119 agonists for treatment of metabolic disorders. WO2017175068. 2017.
   Google Scholar
• Jones RM, Leonard JN, Buzard DJ, et al. GPR119 agonists for the treatment of type 2 diabetes. J Expert Opin Ther Pat. 2009;19:1339–1359.
   PubMed Web of Science ®Google Scholar
• Fyfe MC, McCormack JG, Overton HA, et al. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity. Expert Opin Drug Discov. 2008;3:403–413.
   PubMed Web of Science ®Google Scholar
• Yang JW, Kim HS, Choi YW, et al. Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes Obes Metab. 2018;20:257–269.
   PubMed Web of Science ®Google Scholar
• Cornall LM, Mathai ML, Hryciw DH, et al. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? Expert Opin Investig Drugs. 2013;22:487–498.
   PubMed Web of Science ®Google Scholar
• Mo XL, Yang Z, Tao YX. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus. Prog Mol Biol Transl Sci. 2014;121:95–131.
   PubMed Web of Science ®Google Scholar
• Jang YK, Lee KM, Jung KY, et al. Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists. Bioorg Med Chem Lett. 2017;27:3909–3914.
   PubMed Web of Science ®Google Scholar
• Kato M, Furuie H, Kamiyama E, et al. Safety and pharmacokinetics of DS-8500a, a novel GPR119 agonist, after multiple oral doses in healthy Japanese males. Clin Drug Investig. 2018;38:519–525.
   PubMed Web of Science ®Google Scholar
• Han T, Lee BM, Park YH, et al. YH18968, a novel 1,2,4-triazolone G-protein coupled receptor 119 agonist for the treatment of type 2 diabetes mellitus. Biomol Ther (Seoul). 2018;26:201–209.
   PubMed Web of Science ®Google Scholar
• Wacker DA, Wang Y, Broekema M, et al. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J Med Chem. 2014;57:7499–7508.
   PubMed Web of Science ®Google Scholar
• Spasov AA, Kosolapov VA, Babkov DA, et al. Effect of GRP119 receptor agonist, compound MBX-2982, on activity of human glucokinase. Bull Exp Biol Med. 2017;163:695–698.
   PubMed Web of Science ®Google Scholar
• Schwink L, Bossart M, Glombik H, et al. Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. WO2014056938. 2014.
   Google Scholar
• Schwink L, Buning C, Glombik H, et al. Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. WO2015150563. 2015.
   Google Scholar
• Schwink L, Buning C, Glombik H, et al. Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. WO2015150564. 2015.
   Google Scholar
• Schwink L, Buning C, Glombik H, et al. Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. WO2015150565. 2015.
   Google Scholar
• Schwink L, Buning C, Glombik H, et al. Azetidine compounds as GRP119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. WO2018153849. 2018.
   Google Scholar
• Schwink L, Buning C, Glombik H, et al. Azetidine compounds as GRP119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders. US20180237419. 2018.
   Google Scholar
• Shintani Y, Niwa M, Monma S, et al. Substituted azole compounds, GPR119 agonists containing them, and their use as therapeutic agents for diabetes. WO2015170775. 2015.
   Google Scholar
• Cow CN, Epple R, Nikulin V, et al. Preparation of piperidine derivatives as GPR119 modulators for treatment of diabetes, obesity, and related metabolic disorders. WO2014052619. 2014.
   Google Scholar
• Han TD, Jung EH, Yi CH, et al. Novel triazolone derivatives or salts thereof as GPR119 activators and pharmaceutical composition comprising the same for diabetes treatment. WO2014175621. 2014.
   Google Scholar
• Kim Y, Lee C, Choi D, et al. Pyrrolidinecarboxamide derivatives as GPR119 agonist and their preparation and use for the treatment of metabolic disorders. WO2015080446. 2015.
   Google Scholar
• Yang J, Kim JW, Lee HK, et al. Piperazine derivative as GPR119 activator and method for the preparation thereof. WO2014077532. 2014.
   Google Scholar
• Yang J, Kim JW, Lee K, et al. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient. WO2017078352. 2017.
   Google Scholar
• Qiu N, Chen JY, Yang T Phenyl pyrimidine derivative as GPR119 inhibitor for prevention and treatment of metabolic disorder and its preparation. CN106279041. 2017.
   Google Scholar
• Ahn JH, Bae EJ, Lee IK, et al. Piperidine-aryl derivatives or pharmaceutically acceptable salt thereof, method for preparing same, and pharmaceutical composition containing same as active ingerdient. WO2018160024. 2018.
   Google Scholar
• Chafeev M Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and uses thereof as agonists of G protein-coupled receptor 119. WO2019104418. 2019.
   Google Scholar
• Lu MJ, Zhang HY, Wang GC Preparation of quinolinone derivatives and their application in the treatment of diabetes. CN104447693. 2016.
   Google Scholar
• Yang Z, Fang Y, Liu R, et al. Preparation of fused pyrimidine derivatives useful as GPR119 agonists. CN110256461. 2020.
   Google Scholar
• Yang Z, Fang Y, Jin Y, et al. Tetrahydropyridopyrimidine derivative, preparation and application. CN110256420. 2020.
   Google Scholar
• Fang Y, Zhang S, Wu W, et al. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators. Bioorg Chem. 2020;94:103390.
   PubMed Web of Science ®Google Scholar
• Yang JS, Baek GM, Kim YJ, et al. Compounds having GPR119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component. WO2016068453. 2016.
   Google Scholar
• Cai ZY Preparation of halogenated benzenesulfonylhydrazines as GPR119 agonists. CN104592065. 2016.
   Google Scholar
• Cai ZY Preparation of cyanophenylsulfonyl hydrazine structure containing compounds as GPR119 agonists for treatment of type II diabetes mellitus. CN104628612. 2016.
   Google Scholar
• Cai ZY Preparation of alkyl substituted benzenesulfonyl hydrazides as GPR119 agonists. CN104610105. 2016.
   Google Scholar
• Cai ZY. N-(4-(3-(4-Substituted-5,6,7,8-tetrahydronaphthalen-1-yl)ureido)phenyl) −2-(phenylsulfonyl)hydrazinecarboxamides as GPR119 agonists and their preparation method and application in preparation of medicines for treatment of type-II diabetes. CN104649937. 2015.
   Google Scholar
• Cai ZY GPR119 agonist N-(4-(3-(4-chloro-5,6,7,8-tetrahydronaphthalen-1- yl)ureido)phenyl)-2-((methoxyphenyl)sulfonyl)hydrazinecarboxamide, its preparation method and application in preparation of medicines for treatment of type-II diabetes. CN104649944. 2016.
   Google Scholar
• Yu B, Xie X, Zhang SY, et al. Preparation of Gordonoside F and derivatives for treating GPR119-mediated disease. CN103755762. 2014.
   Google Scholar
• Zhang YY G protein coupled receptor agonist for treatment of diabetes. CN108117545. 2018.
   Google Scholar
• Yang SQ, Wang Y, Liu LG, et al. Spiro ketal derivative, its preparation method and application in preparing the medical formulations as GPR119 agonist for treating diabetes. CN104592245. 2015.
   Google Scholar
• Acton JJ, Edmondson SD, Liu P, et al. Substituted cyclopropyl compounds. WO2014052379. 2014.
   Google Scholar
• Kelley DE, Liu P, Wood HB, et al. Methods of preventing or treating hypoglycemia by administering a GPR119 agonist. WO2017106112. 2017.
   Google Scholar
• Liu P, Hu Z, DuBois BG, et al. Design of potent and orally active GPR119 agonists for the treatment of type II diabetes. ACS Med Chem Lett. 2015;6:936–941.
   PubMed Web of Science ®Google Scholar
• Hamiton J, Kotsikorou E. Parameterization of the GPR119 Receptor Agonist AR231453. J Comput Chem. 2018;39:35–41.
   PubMed Web of Science ®Google Scholar
• Kaushik AC, Kumar A, Rehman AU, et al. Deciphering G-protein-coupled receptor 119 agonists as promising strategy against type 2 diabetes using systems biology approach. ACS Omega. 2018;3:18214–18226.
   Web of Science ®Google Scholar
• Barba O, Bradley SE, Fyfe MCT, et al. Compounds for the treatment of metabolic disorders. WO2009034388. 2009.
   Google Scholar
• Li G, Huan Y, Yuan B, et al. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents. Eur J Med Chem. 2016;124:103–116.
   PubMed Web of Science ®Google Scholar
• Huan Y, Jiang Q, Li G, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017;7:4351.
   PubMed Web of Science ®Google Scholar
• Li G, Meng B, Yuan B, et al. The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119. Eur J Med Chem. 2020;188:112017.
   PubMed Web of Science ®Google Scholar